Vol.3 No.4 (December 2013)
Prediction of Renal Damage Complicated by Hypertension With Uric Acid and Serum Cystatin C as Early Marker
>Abstract: Objective: To determine whether blood uric acid and serum cystatin C were early biomarkers of renal dam- age secondary to hypertension. Methods: A total of 151 eligible patients were enrolled in this prospective study. Ac- cording to the rate of kidney damage, the patients were divided into hypertension group (group I) and hyper-tensive renal injury group (groupⅡ). The concentrations of blood uric acid, creatinine and urea nitrogen were measured by automatic chemistry analysis and the concentration of serum cystatin C was measured by immune transmission nephelometry. The results were compared with those in control group and the evaluation was etrospectively analyzed. Results: The blood uric acid and serum cystatin C-positive rates of group I and groupⅡwere significantly higher than those of the control group (P < 0.01). However, the blood uric acid and serum cystatin C-positive rates in hypertensive patients were significantly higher than the blood urea and serum creatinine-positive rates (P < 0.01). In addition, the blood uric acid and serum cystatin C in hypertensive patients increased far earlier than blood urea and serum creatinine did. Conclusion: The blood uric acid and serum cystatin C are the sensitive indicators of hypertension with early renal damage. The sensitivity of blood uric acid and serum cystatin C is higher than that of the blood urea and serum creatinine. Therefore, detection of blood uric acid and serum cystatin C level has important clinical value in the diagnosis of hypertension with early renal damage.
彭家清 (2013) 尿酸和血清胱抑素C对高血压肾损害早期诊断的预测价值。 临床医学进展， 3， 25-28. doi: 10.12677/ACM.2013.34007
 Bagshaw, S.W. and Gibney, R.T. (2008) Conventional markers of kidney function. Crit Care Med, 36, S152-S158.
 陆再英, 钟南山, 主编 (2008) 内科学. 北京人民卫生出版社, 北京, 51-262.
 Mule, G., Cottone, S., Nardi, E., et a1. (2006) Metabolic syndrome in subjects with essential hypertension: Relationships with subclinical cardiovascular and renal damage. Minerva Car- dioangiologica, 54, 173-194．
 Talaat, K.M. and EI-Sheikh, A.R. (2007) The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. American Journal of Nephrology, 27, 435-440．
 Convento, M.S., Pesson, E., Dalboni, M.A., et al. (2011) pro- inflammatory and oxidative effect of noncrystalline uric acid in human mesangial cells: Contribution to hyperuricemic glomerular damage. Urological Research, 39, 21-27.
 Qian, Q., Kassem, K.M., Beierwaltes, W.H., et al. (2009) PGE2 causes mesangial cell hypertrophy and decreases expression of cyclin D3. Nephron Physiology, 113, 7-14.
 Luc, G., Bard, J.M. and Lesueur, C. (2006) Plasma cystatin-C and development of Coro-nary heart disease: The PRIME Study. Atherosclerosis, 18, 375-380.
 Bokenkamp, A., Herget-Rosenthal, S., Bokenkamp, R. and Cystatin, C. (2006) kidney function and cardiovascular rdisease. Pediatric Nephrology, 21, 1223-1230.
 Madero, M., Sarnak, M.J. and Stevens, L.A. (2006) Serum cystatin C as a marker of glomerular filtrationrate. Current Opinion in Nephrology and Hypertension, 15, 610-616.